mRNA기반으로 하는 폐암백신의 임상이 시작되었다.
https://v.daum.net/v/20240823141726402
"30분 동안 여섯 번 주사"...60대男 세계 두번째로 '이 백신' 맞은 사연은?
지금껏 백신 접종으로 예방이 가능한 암은 자궁경부암이 유일했던 가운데, 다른 암도 백신으로 예방할 수 있는 시대가 가까이 오고 있다. 지난 7월 말 세계 최초로 폐암 백신 접종 임상 시험이
v.daum.net
https://www.biontech.com/int/en/home/pipeline-and-products/pipeline.html
BioNTech | Technologies for customized treatment approaches
Whether mRNA, cell therapies, antibodies or small molecule immunomodulators | learn all about our technical approaches for oncology and infectious diseases.
www.biontech.com
https://jitc.bmj.com/content/11/Suppl_1/A679
597 Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen RNA vaccine BNT116 in p
Background BNT116 is an intravenously administered RNA-lipoplex therapeutic cancer vaccine comprising six RNAs each encoding a tumor-associated antigen (TAA) frequently expressed in non-small cell lung cancer (NSCLC). Here, we report preliminary results fr
jitc.bmj.com
BNT116 is an intravenously administered RNA-lipoplex therapeutic cancer vaccine comprising six RNAs each encoding a tumor-associated antigen (TAA) frequently expressed in non-small cell lung cancer (NSCLC). Here, we report preliminary results from patients with advanced unresectable or metastatic NSCLC (ECOG 0–2) receiving BNT116 monotherapy with optional addition of cemiplimab.
Cemiplimab
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.
https://en.wikipedia.org/wiki/Cemiplimab
Cemiplimab - Wikipedia
From Wikipedia, the free encyclopedia Pharmaceutical drug Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication for the treatment of squamous cell skin cancer.[7][8] Cemiplimab belongs to a class of drugs that binds to the prog
en.wikipedia.org
'신약개발 소식, 해외 논문들' 카테고리의 다른 글
| Amivantamab + lazertinib (CHRYSALIS-2) (0) | 2024.09.10 |
|---|---|
| 유한양행 렉라자, FDA 허가…비소세포폐암 1차 치료제 승인 (0) | 2024.09.09 |
| NK세포치료-세툭시맙 요법, EGFR 변이 폐암 효과 규명 (0) | 2024.07.10 |
| HLB "리보세라닙, 폐암 3기 전환치료에서 완전관해" (0) | 2024.06.15 |
| 파트리투맙 데룩스테칸 Patritumab deruxtecan (HER3-DXd, U3-1402) (0) | 2024.03.26 |